Intellectual Property - September 4, 2017
Patent granted for Moberg Pharma’s BUPI
Moberg Pharma announces that the Canadian Patent Office has issued Patent No. 2 860 373 which protects BUPI, currently in development for pain due to oral mucositis. The Canadian patent covers the use of a lozenge comprising a local anesthetic, e.g. bupivacaine, in a number of different indication, including treatment of pain due to oral […]
Clinical Trials - October 29, 2014
Moberg Pharma enters Phase II
Moberg Pharma announced that the first patient has been included in a randomized controlled phase II study with BUPI, a novel topical formulation for the treatment of oral pain. The aim is to confirm the promising results gained from several smaller pilot studies and to evaluate if bupivacaine formulated as a lozenge can be an […]
